Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
1.683
+0.083 (5.19%)
At close: Mar 9, 2026, 4:00 PM EDT
1.670
-0.013 (-0.78%)
After-hours: Mar 9, 2026, 4:00 PM EDT
Traws Pharma Revenue
Traws Pharma had revenue of $2.85M in the twelve months ending September 30, 2025, up 1,159.29% year-over-year. In the year 2024, Traws Pharma had annual revenue of $226.00K.
Revenue (ttm)
$2.85M
Revenue Growth
+1,159.29%
P/S Ratio
4.49
Revenue / Employee
$406,571
Employees
7
Market Cap
13.45M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLineRx | 12.74M |
| Curis | 11.65M |
| BioAtla | 11.00M |
| CytoMed Therapeutics | 573.19K |
| BioCardia | 3.00K |
| Soligenix | 2.34K |
TRAW News
- 18 days ago - Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza - GlobeNewsWire
- 7 weeks ago - Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients - GlobeNewsWire
- 4 months ago - ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials - PRNewsWire
- 4 months ago - Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. - PRNewsWire
- 5 months ago - Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 - GlobeNewsWire
- 7 months ago - Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 - GlobeNewsWire
- 7 months ago - Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Traws Pharma Reports Second Quarter 2025 Results and Business Highlights - GlobeNewsWire